Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 5 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 4 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Psoriasis study shows high level of arthritis symptoms in patients
Medical Xpress· 4 days agoThe study led by researchers at the Universities of Oxford, University College Dublin and supported...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 4 hours agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
The Best LED Face Masks To Improve Wrinkles And Acne, According To Dermatologists
Women's Health via AOL· 2 days agoThe best FDA-approved LED light therapy face masks, per dermatologists and editors, have benefits...
Yale dermatologist points to link between skin con | Newswise
Newswise· 3 days ago..., Assistant Professor and Director of the Psoriasis Treatment Program at Yale School of Medicine,...
13 Best Shampoos for Thinning Hair, According to Hair and Skin Experts
Prevention via AOL· 2 days agoWe reviewed the best shampoos for thinning hair, per dermatologists. Our top picks reign from brands...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks· 2 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Vanguard Group Inc. Acquires 6,572 Shares of Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 5 days agoVanguard Group Inc. boosted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission ...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the ...
Morningstar· 2 days agoFood and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. The submission ...